^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Lartruvo (olaratumab) (PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LARTRUVO (olaratumab) approved in Canada for the treatment of advanced soft tissue sarcoma in adults
Published date:
01/24/2018
Excerpt:
Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for LARTRUVO (olaratumab). Olaratumab is a chemotherapy medicine used in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma when treatment with radiation or surgery are not options.
Secondary therapy:
doxorubicin hydrochloride
Source:
Published date:
11/09/2016
Excerpt:
Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma…
Secondary therapy:
doxorubicin hydrochloride
Source:
Excerpt:
LARTRUVO™ is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
Secondary therapy:
doxorubicin hydrochloride
Source:
Title:
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Summary of recommendations...Management of advanced/metastatic disease...The combination of doxorubicin with an anti-PDGFRA agent, olaratumab, is option [II, C].
Secondary therapy:
doxorubicin hydrochloride
DOI:
10.1093/annonc/mdy310
